Critical Limb Ischemia

Black and Hispanic patients with peripheral artery disease experience worse limb outcomes compared with white patients, even when presenting at a similar stage of clinical severity, data show.

Peripheral artery disease and its most advanced form, critical limb ischemia, are major sources of morbidity and mortality, yet many patients are not diagnosed in time to prevent amputation.

Among patients with critical limb ischemia, nearly two-thirds did not have revascularization or angiography before undergoing major amputation, researchers reported at VIVA 21.

Among patients with critical limb ischemia, nearly two-thirds did not have revascularization or angiography before undergoing major amputation, researchers reported at VIVA 21.

The FDA granted orphan drug designation to CLBS12, an investigational nongene-edited cell therapy for the treatment of Buerger’s disease, according to the agent’s manufacturer.

The FDA’s Circulatory System Devices Panel voted not to recommend approval of a drug-coated balloon to treat below-the-knee lesions in patients with critical limb ischemia.

Pedra Technology announced the FDA granted breakthrough device designation for periprocedural use of its perfusion system for the treatment of critical limb ischemia.

In the single-arm PROMISE I study of deep venous arterialization in patients with severe critical limb ischemia, seven of 10 survived and were free from amputation at 1 year, according to data presented at the virtual VIVA 20.

Among patients with peripheral artery disease who had an endovascular procedure, treatment with a drug-coated device was linked to lower risk for unplanned limb revascularization, according to new data from the VOYAGER PAD trial.

Critical limb ischemia, also known as chronic limb-threatening ischemia, is an undertreated disease that often leads to amputation and/or mortality. One reason for undertreatment and underdiagnosis was coding.